Drug Profile
Research programme: cardiac arrhythmia gene therapy - Sanofi/Excigen
Alternative Names: Gene therapy for cardiac arrhythmiasLatest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Excigen; Genzyme Corporation
- Developer Excigen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atrial fibrillation
Most Recent Events
- 04 May 2006 No development reported - Preclinical for Atrial fibrillation in USA (unspecified route)
- 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation
- 25 Mar 2003 Preclinical trials in Atrial fibrillation in USA (unspecified route)